We evaluated a 50-year-old man with a history of recurrent sinusitis. Computed tomography (CT) of the sinuses revealed chronic bilateral ethmoid sinusitis with totally opacified ethmoid cells. The patient underwent bilateral endoscopic ethmoidectomies. At the time of surgery, bilateral openings were found lateral to the insertion of the middle turbinates (figure, A and B). Gentle probing revealed a patent passage toward the medial canthus of the eye (figure, C). Transillumination with a 0°telescope inserted into the passage confirmed patent dacryocystorhinostomies (DCRs) bilaterally (figure, D) .
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